Guo 2015c.

Methods	Study design: Randomised clinical trial Study duration: February 2011 to January 2013 Duration of follow‐up: 1 year Setting: Hospital
Participants	Age (mean ± SD): 51.8 ± 9.6 years Male (n/total): 47/72 Tumour diameter: 6.3 ± 2.5 cm Child‐Pugh Class: Class A: 9; Class B: 46; Class C: 17
Interventions	TACE + ultrasound ablation group (n = 36): TACE: Chemotherapeutic drugs: 10‐40 mg epirubicin Ultrasound ablation frequency 0.96 MHz, focal length 134 mm TACE group (n = 36): Chemotherapeutic drugs: 10‐40 mg epirubicin
Outcomes	Tumour response: measured by image examinations at 1 month after treatment Clinical efficacy Serum level of AFP 1‐year survival rate Adverse events
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.